pharmaphorum

AUGUST 31, 2022

In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.

Chemotherapy 116

Chemotherapy Immunization Immunity Hospitals 116

pharmaphorum

OCTOBER 4, 2020

However it requires high-dose chemotherapy to destroy the bone marrow, and that poses significant risks to patients in its own right, and can also lead to graft-versus-host disease, a potentially life-threatening complication in which the bone marrow donor’s immune cells attack the recipient’s cells and tissues.

Immunization 98

Immunization Immunity Chemotherapy 98

European Pharmaceutical Review

APRIL 10, 2024

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.

Immunization 95

Immunization Immunity Chemotherapy Diabetes 95

Big Molecule Watch

OCTOBER 31, 2023

The active ingredient in LOQTOZI, toripalimab, is a monoclonal antibody that binds programmed death receptor-1 (PD-1) and blocks its interactions with ligands PD-L1 and PD-L2 with high potency, enabling the immune system to activate and kill the tumor. LOQTORZI is expected to be available in the United States in Q1 2024.

Chemotherapy 49

Chemotherapy Immunization Immunity 49

European Pharmaceutical Review

DECEMBER 28, 2023

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

Immunization 84

Immunization Immunity Chemotherapy Medical Schools 84

European Pharmaceutical Review

JUNE 27, 2023

difficile infection by the end of 2024 and will be announcing first patient dosed in the Phase II clinical trial of VE202 for ulcerative colitis (UC) shortly too. How do you envision microbiome therapies complementing existing cancer treatments, such as chemotherapy and immunotherapy?

Immunization 105

Immunization Immunity Chemotherapy Vaccines 105

PharmaShots

MARCH 29, 2023

It is the only drug in its class of chemotherapy and is developed from the natural substance found in a sea sponge. According to the Novo Nordisk legal settlement with its competitors, though the Victoza patent expires in 2023, the drug wouldn’t face generic competition until 2024.

Biosimilars 49

Biosimilars Diabetes Chemotherapy Immunization 49

The Thyroid Pharmacist

SEPTEMBER 20, 2024

Chemotherapy agents: Chemotherapy agents can lead to constipation in a variety of ways such as slowing the movements of the intestinal tract or creating inflammation that disrupts digestive function. Accessed September 6, 2024. Accessed September 17, 2024. freece.com. [11] 11] Bhattacharjee B, Upadhyay S, Ghosh J.

Health and Personal Care Stores 75

Health and Personal Care Stores Diabetes Chemotherapy Medication Therapy Management (MTM) 75

European Pharmaceutical Review

FEBRUARY 3, 2025

Biosimilars given a positive opinion Dyrupeg (pegfilgrastim) to reduce the duration of neutropenia and help prevent febrile neutropenia following chemotherapy. The EC questioned whether this would necessitate an update of the CHMPs opinion made in November 2024.

Vaccines 52

Vaccines Generic Medicine Chemotherapy Biosimilars 52